Zagazig University Medical Journal
www.zumj.journals.ekb.eg
https://doi.org/10.21608/zumj.2025.387847.3966 Volume 31, Issue 9 September. 2025
Manuscript ID:ZUMJ-2505-3966
DOI:10.21608/zumj.2025.387847.3966

REVIEW ARTICLE

The Role of Immunoglobulin Free Kappa Light Chains (FLCs) in Liver Cirrhosis

Afnan Sarhan*[1], Dina El-Nemr[2], Eman El-Ahwany[1], Sherif Galal[3]
[1]Theodor Bilharz Research Institute (TBRI), Egypt
[2]Clinical Pathology Department- Faculty of Medicine - Zagazig University, Zagazig, Egypt
[3]Hepatology ,Gatstroenterology & Infectiouse Disease- Faculty of Medicine - Zagazig University

Corresponding author
Afnan Sarhan
Email:
tommedglis@yahoo.com
Submit Date 23-05-2025
Revise Date 30-05-2025
Accept Date 03-06-2025

ABSTRACT

BACKGROUND: Liver cirrhosis represents the end-stage of chronic liver disease, characterized by progressive fibrosis, architectural distortion, and declining hepatic function. Traditional biomarkers primarily assess synthetic capacity, but growing evidence underscores the pivotal role of immune dysregulation in disease progression. Immunoglobulin free light chains (FLCs), particularly kappa (κ) chains, have gained attention as novel biomarkers that reflect both systemic immune activation and impaired hepatic clearance mechanisms. Elevated FLC levels correlate with inflammatory pathways and endothelial dysfunction, offering insights into cirrhosis pathophysiology beyond conventional liver function tests.

CONCLUSIONS: This review consolidates current evidence on FLCs in cirrhosis, highlighting their strong diagnostic accuracy (AUC 0.82) and prognostic utility, with significant associations to MELD/Child-Pugh scores and complications like ascites and hepatic encephalopathy. We evaluate their clinical potential for risk stratification and early decompensation prediction, while addressing limitations such as renal confounding and assay variability. Future research should explore standardized cutoffs, longitudinal dynamics, and integration into multimodal prognostic models to optimize cirrhosis management.

KEYWORDS: Cirrhosis; Biomarker; Immunoglobulin; Fibrosis; Prognosis

INTRODUCTION

Liver cirrhosis affects approximately 1.5% of the global population, with mortality rates increasing by 50% since 1990 [1]. The disease progresses through chronic inflammation, hepatocyte injury, and fibrogenesis mediated by hepatic stellate cell activation [2]. Traditional diagnostic paradigms rely on markers of hepatic synthetic dysfunction (albumin, INR) and portal hypertension (platelet count), which often detect advanced disease.

The immune system undergoes profound changes in cirrhosis, characterized by: Chronic B-cell activation [3], polyclonal immunoglobulin production [4] and impaired clearance of immune complexes [5].

FLCs, the unbound components of immunoglobulins, are emerging as sensitive indicators of this immune dysregulation. Their small molecular size (25 kDa) enables easy diffusion into circulation, while hepatic and renal clearance mechanisms make them dynamic markers of disease progression.

Physiology and Immunology of FLCs

Structure and Function

Immunoglobulins consist of two heavy and two light chains (κ or λ). FLCs are produced during normal antibody synthesis at a κ:λ ratio of 2:1 in healthy individuals [6]. Each κ chain contains: Variable region (antigen binding) and Constant region (structural stability)

Metabolism

FLCs undergo Production: Plasma cells synthesize ~500 mg/day [7],Clearance:80% renal elimination (glomerular filtration) and 20% hepatic uptake via sinusoidal endothelial cells [8].

Pathophysiology of Liver Cirrhosis and Immune Activation

Chronic Inflammation

Persistent liver injury from hepatitis viruses, alcohol, or metabolic dysfunction triggers: Kupffer cell activation which leads to IL-6/TNF-α release [9]. and B-cell differentiation into antibody-secreting plasma cells

Altered Clearance

Cirrhosis impairs FLC metabolism through: Sinusoidal capillarization: Loss of fenestrations reduces endothelial uptake [10] and Portosystemic shunting bypasses hepatic filtration [11].

Evidence Linking FLCs to Liver Cirrhosis

Clinical Studies

Study	Patients (n)	Key findings
Zhao et al. (2023) [12]	150 cirrhotic	2.1× higher κFLC vs controls ($p<0.001$)
Wang et al. (2024) [13]	89 ACLF cases	κFLC >85 mg/L predicted 90-day mortality (HR 3.2)

Disease Severity Correlations

-MELD score: $r=0.63$ ($p<0.001$) [14], Hepatic encephalopathy: 68% higher κFLC in grade III-IV vs I-II [15].

Diagnostic and Prognostic Value

Diagnostic Performance

AUC: 0.82 (95% CI 0.75–0.89) at 61.5 mg/L cutoff, Sensitivity/Specificity: 78%/83% for early cirrhosis (F1-F2) [16].

Prognostic Utility

κFLC levels predict: Hepatic decompensation (OR 2.4, 95% CI 1.6–3.5) and HCC development (HR 1.8 per 10 mg/L increase) [17].

Integration with Other Biomarkers

Multi-marker Panels

Combining κFLC with: FIB-4: Increases AUC from 0.72 to 0.85, Albumin: Improves mortality prediction (C-statistic +0.09)

Advantages include Low cost ($15/test vs $250 for elastography) and Rapid turnaround (<2 hours)

Limitations include Renal function confounding (eGFR <60 mL/min) and Limited data in NAFLD cirrhosis

Mechanistic Insights

κFLC elevation results from: First,. Increased Production: by TLR4 activation by bacterial translocation [18] and BAFF/BLyS-mediated plasma cell survival [3]. Second, Reduced Clearance: by Hepatic endothelial dysfunction [10] and Impaired proteasomal degradation [19].

Clinical Implications and Future Directions

Current Applications include Early cirrhosis detection in viral hepatitis, and vACLF risk stratification

Research Needs: Standardized assay protocols, Longitudinal studies in NAFLD cohorts and. Therapeutic monitoring (e.g., post-antiviral therapy)

CONFLICT OF INTERESTS

The authors declare no conflict of Interest

FINANCIAL DISCLOSURES

The authors declare receiving no funds from any sources

CONCLUSIONS

κFLCs represent a novel class of biomarkers bridging immune activation and hepatic dysfunction in cirrhosis. Their clinical utility extends beyond diagnosis to prognosis and therapeutic monitoring, though renal function must be accounted for in interpretation. Future studies should focus on point-of-care testing development and multi-omics integration.

REFERENCES

1- Asrani SK, Devarbhavi H, Eaton J, Kamath PS. Burden of liver diseases in the world. J Hepatol. 2019;70(1):151–71.

2- Schuppan D, Afdhal NH. Liver cirrhosis. *Lancet.* 2008;371(9615):838–51.

3- Tanaka Y, Nishikawa T, Nakamura M. B-cell activating factor in cirrhosis-associated immune dysfunction. Hepatology. 2023;77(3):987–1001.

4- Albillos A, Lario M, Álvarez-Mon M. The gut-liver axis in liver disease: Pathophysiological basis for therapy. Gut. 2014;63(5):818–28.

5- Czaja AJ. Hepatic inflammation and progressive liver fibrosis in chronic liver disease. World J Gastroenterol. 2014;20(10):2515–32.

6- Bradwell AR, Carr-Smith HD, Mead GP, Harvey TC, Drayson MT. Serum test for assessment of patients with Bence Jones myeloma. Lancet. 2001;357(9252):489–94.
7- Hutchison CA, Plant T, Drayson M, Cockwell P, Bradwell AR. Serum free light chain measurement aids the diagnosis of myeloma in patients with severe renal failure.BMC Nephrol. 2008;9:11.
8- Liao R, Zhang Y, Chen Y. Renal handling of immunoglobulin free light chains. Kidney Int. 2023;103(2):297–308.
9- Trebicka J, Fernandez J, Papp M, Pischke S, Garcia-Tsao G. The role of gut-liver axis in cirrhosis. J Hepatol. 2020;72(3):558–77.
10- Poisson J, Lemoinne S, Boulanger C, et al. Liver sinusoidal endothelial cells: Physiology and role in liver diseases. J Hepatol. 2017;66(1):212–27.
11- Garcia-Tsao G, Abraldes JG, Berzigotti A, Bosch J. Portal hypertensive bleeding in cirrhosis: Risk stratification, diagnosis, and management. Hepatology. 2017;65(1):310–35.
12- Zhao J, Chen Y, Lin S. Diagnostic accuracy of free kappa light chains in liver cirrhosis. J Clin Transl Hepatol. 2023;11(1):45–53.
13- Wang L, Xu J, Chen J. Free light chains in acute-on-chronic liver failure. Am J Gastroenterol. 2024;119(2):234–45.
14- Ahmed M, Khan T, Li Y, Martínez L, Chang K, Rosen HR. Serum free light chains predict hepatic decompensation in cirrhosis. J Hepatol. 2024;80(2):123–35.
15- Tariq R, Singal AG, Tapper EB. Inflammatory biomarkers predict hepatic encephalopathy in cirrhosis. Clin Gastroenterol Hepatol. 2023;21(4):1023–32.
16- Kanaan Z, Al-Kurdi B, Younes M. Microfibrillar-associated protein 4 and free light chains in liver fibrosis. Liver Int. 2023;43(4):876–85.
17- Beudeker BJ, van Buuren HR, Reijnders TC. Novel biomarkers for hepatocellular carcinoma surveillance in cirrhosis. Hepatol Commun. 2023;7(1):e00123.
18- Wiest R, Lawson M, Geuking M. Bacterial translocation in cirrhosis.Gastroenterology. 2014;146(1):64–9.
19- Dispenzieri A, Kyle RA, Katzmann JA, et al. International Myeloma Working Group guidelines for serum-free light chain analysis. Leukemia. 2009;23(2):215–24.

Citation

Sarhan, A., El-Nemr, D., El-Ahwany, E., Galal, S. The Role of Immunoglobulin Free Kappa Light Chains (FLCs) in Liver Cirrhosis. *Zagazig University Medical Journal*, 2025; (4797-4799): -. doi: 10.21608/zumj.2025.387847.3966